該当箇所へ

ポスター:遺伝子治療薬における次世代シーケンス(NGS)を用いた重要品質特性(CQA)の同定

September 1, 2022

In the race to make life-changing gene therapies more accessible, maintaining in-process critical quality attributes (CQAs) remains necessary to guarantee the delivery of safe and effective treatment. CQAs such as Identity, Potency, and Safety, can be efficiently monitored by implementing Next-Generation Sequencing (NGS) at various stages of development and manufacturing.  

Download this poster to learn how the NGS-based workflows of Genedata Selector® eliminate the need for implementing multiple different assays to determine CQAs and discover:

  • How our technology agnostic platform supports all types of NGS-based assays throughout the GT vector development process 
  • How the platform's wizard-based Playbooks simplify and automate NGS-based assays for GT development 
  • How the platform enables data traceability for all analyses and report generation for internal and external audits
  • How the platform facilitates integrity analysis and provides clear go/no-go thresholds for faster and better-informed decisions

資料をリクエスト

本フォームを送信することで、Genedata プライバシーポリシー に従い個人情報が収集・利用されることへ同意します。